ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like Tax Reform: A War on Life Sciences Innovation December 11, 2017 GlaxoSmithKline Poaches Another Top Exec—This Time From Pfizer July 12, 2017 Catalent Reports Second Quarter Fiscal Year 2017 Results February 6, 2017
